NTRA - Natera: Why COVID-19 Will Bring Out Q2 Shorts Leaving 2021 A Buy
Source: Natera Inc.
Introduction: what is Natera?
Formed in 2003, Natera Inc. (NTRA) has since become a major player in the diagnostics market operating with proprietary molecular and bioinformatics technology aiming to change the way global diseases are managed. They generate revenue primarily in the USA from the sale of self-developed genetics tests, primarily Panorama and Horizon. Their portfolio focuses on three areas: reproductive health, oncology, and organ transplant rejection.
Investment Thesis:
After analyzing Natera's financial situation and strategy including cash burn risk, growth opportunities, and key buyer factors during and forecasted